Lundbeck Still Assessing Future Of Antipsychotic After Phase III Failure, Says CEO
Executive Summary
Deborah Dunsire, Lundbeck’s new CEO, talks to Scrip about the fallout from its recent Phase III setback, and how she sees the road ahead for CNS clinical research.
You may also be interested in...
Lundbeck Boosts US R&D Capability With $400m Abide Theraputics Bid
Danish neuroscience company plans to acquire Abide Therapeutics for $250m upfront and up to $150m in milestones to access serine hydrolase drug discovery platform.
The Darkest Hour Is After DAYBREAK For Lundbeck’s New Antipsychotic
The first Phase III study for Lundbeck’s novel antipsychotic flops leaving the Danish company shares down by 25% as investors wonder what’s left in the pipeline.
Investment And Acquisition In Rare Diseases
In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.